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I N PREVIOUS publications,I,2 it was 
suggested that thoracic duct drainage 
(TOO) should be used for at least 28 days 
before renal transplantation in order to 
achieve the maximum benefit of this 
lymphoid-depleting procedure. Further expe-
rience has reinforced this conclusion. The 
lines of evidence are as follows. 
KIDNEY AND PATIENT SURVIVAL 
In Fig. 1 are shown the kidney survival 
curves in primary cadaveric recipients who 
were treated with: (1) azathioprine and pred-
nisone to which an ineffective ALG was often 
added; (2) the same, but with TOO starting 
on the day of transplantation; (3) the same, 
with TOO treatment prior to transplantation 
for 17-27 days; and (4) the same, with TOO 
pretreatment 28 days or more. 
Kidney survival was better in all TOO 
groups than in patients treated with conven-
tional immunosuppression alone. The best 
results were achieved with pretreatment of 
;:0:28 days (Fig. 1). The 22 patients who were 
pretreated ;:0:28 days had only a single rejec-
tion (4.5%) in the first 3 months. 
The actual as well as actuarial patient 
mortality was not greater in the TOO series 
than in the retrospective controls, and indeed 
it was slightly less (Fig. 2). 
HUMORAL ANTIBODIES AFTER 
TRANSPLANTATION 
Warm anti-T and/or anti-B-Iymphocyte 
antibodies3 in response to transplantation 
were measured in 19 patients who were 
pretreated for 16-27 days and in the 22 
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THORACIC DUCT DRAINAGE (TOO) VS. CONTROL 
PRIMARY CADAVERIC RENAL GRAFT SURVIVAL 
Fig. 1. One-year actuarial 
graft survival. TOO pretreat-
ment for 28 days or more 
significantly differs from con-
trols at 3, 6, and 12 months. 
TOO pretreatment of less than 
28 days and contemporaneous 
TOO do not differ from con-
trols. The control group con-
sists of 51 consecutive retro-
spective controls. 
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Fig. 2. Side effects from TOO include occasional 
bacteremia. chylothorax. and rarely wound infection. 
However. TOO does not affect the mortality. 
patients who had TOO for 28 days or more 
before transplantation. Compared to recip-
ients with TOO pretreatment ~OU days, 
patients with shorter periods of preparation 
were still draining large numbers of lympho-
cytes in the last 5 days preceding transplanta-
tion, retained a strong capability to produce 
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warm antibodies, and had a high incidence of 
rejection (Fig. 3). 
CONCLUSION 
The foregoing results explained why the 
primary cadaveric kidneys survived at such a 
high rate in patients conditioned by TOO for 
4 weeks or longer. The immunodepressive 
effect of TOO was not fully established until 
the full 4 weeks. The same conclusion about 
the time curves of TOO effectiveness has been 
reached by Machleder and Paulus4 by immu-
nologic tests in patients being treated for 
autoimmune diseases. 
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NUMBER OF LYMPHOCYTES REMOVED BY TOO LAST 5 DAYS PRIOR TO TRANSPLANT 
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Fig. 3. The incidence of rejection and graft losses from rejection within 3 months aftar transplantation in 
group I. characterized by the largest number of lymphocytes still being present in the last 5 days before 
transplantation; 6/7 patients experienced rejection and 2 grafts were lost. In group II. characterized by removal of 
intermediate numbers of lymphocytes in this pretransplantation period. 6/17 patients had rejections and 3 grafts 
were lost. In group III. characterized by the least number of residual lymphocytes. only 2/17 patients experienced 
rejections and only 1 graft was lost. The incidence of rejection within 3 months between groups I and III and 
between groups I and II differs significantly (p < 0.01 ). In group I. one patient had antibodies before and 6 developed 
antibodies after transplantation. In group II. 2 patients had antibodies before and 7 developed antibodies after 
transplantation. In group III. one patient had antibodies before and 3 developed antibodies after transplantation. 
The ability to form B-warm andl or T -warm antibodies between groups I and II is not quite significant (p < 0.1 ); but 
between groups I and III a significance exists (p < 0.01). There is no statistically significant difference between 
groups II and III. BW. warm anti-B-Iymphocyte antibodies; TW. warm anti-T -lymphocyte antibodies. 
